NPI: 1215151154 · VALPARAISO, IN 46383 · General Acute Care Hospital · NPI assigned 04/12/2007
Authorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
| Authorized Official | LALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL) |
| NPI Enumeration Date | 04/12/2007 |
Other providers sharing the same authorized official: LALOR, PAULA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 65,407 | $1.43M |
| 2019 | 49,098 | $2.55M |
| 2020 | 37,098 | $2.27M |
| 2021 | 65,227 | $4.90M |
| 2022 | 86,372 | $6.60M |
| 2023 | 79,061 | $6.14M |
| 2024 | 56,794 | $4.29M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 60,596 | 50,934 | $8.75M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 39,205 | 31,196 | $5.59M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 6,163 | 1,960 | $2.81M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 16,142 | 14,700 | $1.92M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7,552 | 5,938 | $965K |
| 71045 | Radiologic examination, chest; single view | 7,556 | 5,893 | $893K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3,595 | 2,418 | $854K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 12,844 | 8,759 | $711K |
| 71046 | Radiologic examination, chest; 2 views | 5,022 | 4,226 | $636K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7,720 | 6,642 | $524K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2,845 | 2,507 | $443K |
| 80050 | General health panel | 3,097 | 2,798 | $374K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2,032 | 889 | $330K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 897 | 689 | $324K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1,324 | 993 | $267K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4,356 | 3,578 | $229K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 572 | 450 | $224K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1,275 | 849 | $209K |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2,090 | 1,846 | $208K |
| 80053 | Comprehensive metabolic panel | 38,468 | 28,468 | $194K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 49,704 | 37,055 | $181K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1,728 | 654 | $177K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5,736 | 4,988 | $158K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 918 | 834 | $119K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 6,204 | 5,226 | $117K |
| 36415 | Collection of venous blood by venipuncture | 63,543 | 47,724 | $114K |
| 76820 | 1,804 | 728 | $92K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 835 | 699 | $88K |
| 70450 | Computed tomography, head or brain; without contrast material | 742 | 583 | $71K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 989 | 793 | $67K |
| 84484 | 7,582 | 4,713 | $48K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 3,599 | 2,781 | $45K |
| 81025 | 7,536 | 6,185 | $40K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6,362 | 5,149 | $39K |
| 87430 | 2,809 | 2,544 | $33K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 996 | 803 | $31K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,270 | 1,919 | $30K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 694 | 636 | $29K |
| 83690 | 8,761 | 6,768 | $27K | |
| 81001 | 15,169 | 12,030 | $26K | |
| 96367 | 302 | 123 | $15K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 55 | 39 | $14K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,773 | 1,392 | $14K |
| 59025 | Fetal non-stress test | 65 | 24 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 3,374 | 2,671 | $13K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 47 | 44 | $11K |
| 87081 | 1,906 | 1,722 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2,904 | 2,316 | $10K |
| 82077 | 740 | 626 | $8K | |
| 11043 | 26 | 14 | $8K | |
| 99218 | 14 | 13 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 47 | 44 | $6K |
| 87400 | 317 | 282 | $6K | |
| 80074 | 138 | 130 | $6K | |
| 96417 | 51 | 26 | $5K | |
| 87807 | 377 | 338 | $4K | |
| 80061 | Lipid panel | 551 | 456 | $4K |
| 83735 | 897 | 749 | $4K | |
| 81003 | 2,450 | 1,976 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 20 | 13 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | 468 | 375 | $2K |
| 87806 | 131 | 125 | $2K | |
| 87070 | 339 | 297 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 16 | 16 | $2K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 21 | 12 | $2K |
| 80076 | 209 | 199 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | 169 | 132 | $1K |
| 85027 | 165 | 157 | $921.22 | |
| 86592 | 227 | 217 | $856.89 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 35 | 26 | $806.40 |
| 85610 | 432 | 298 | $523.43 | |
| 86140 | 99 | 82 | $333.07 | |
| 36591 | 242 | 116 | $274.16 | |
| 85379 | 44 | 37 | $267.73 | |
| 82728 | 30 | 24 | $205.83 | |
| 84153 | 13 | 12 | $181.15 | |
| 80069 | 124 | 84 | $128.65 | |
| 87040 | 23 | 13 | $124.81 | |
| 82570 | 67 | 57 | $122.13 | |
| 84460 | 55 | 40 | $101.74 | |
| 85730 | 56 | 41 | $101.13 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 22 | 15 | $100.02 |
| 84450 | 55 | 40 | $99.45 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 39 | 25 | $77.85 |
| 82550 | 16 | 12 | $71.61 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,559 | 2,110 | $68.26 |
| 82043 | 34 | 28 | $65.61 | |
| 82247 | 16 | 12 | $58.44 | |
| 82962 | 38 | 24 | $37.88 | |
| 84156 | 17 | 17 | $21.95 | |
| 81015 | 12 | 12 | $21.35 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 273 | 245 | $18.30 |
| J2704 | Injection, propofol, 10 mg | 3,243 | 2,222 | $14.62 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,872 | 1,422 | $1.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 101 | 68 | $0.00 |
| 99152 | 73 | 54 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 16 | 13 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 108 | 83 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 162 | 137 | $0.00 |
| C1769 | Guide wire | 37 | 28 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 13 | 12 | $0.00 |